Business
-
According to Swedish CRO Medicon Valley Inhalation Consortium (MVIC), the organization has entered into a 2-year, €1.6 million contract with a Chinese company to develop an inhaled generic drug for the treatment of asthma and… Read more . . .
-
Reckitt Benckiser Pharmaceuticals will co-develop a unit-dose naloxone nasal spray for the reversal of opioid overdoses with Kentucky-based AntiOp, the company has announced. The only detail of the deal that was released is that the… Read more . . .
-
As part of an interim management statement, Skyepharma has said that the launch of its Flutiform fluticasone/formoterol MDI in Spain could take place by the end of 2014, triggering a milestone payment of €2.0 million.… Read more . . .
-
Apotex says that it launched a generic budesonide nasal spray in the US on May 13, 2014 following the previous day’s approval of the product by the FDA. The new product, with a strength of… Read more . . .
-
Perrigo has announced that it has begun shipping its generic version of Astepro azelastine nasal spray after the ANDA it submitted in partnership with Impax Laboratories received final approval from the FDA. In January 2012,… Read more . . .
-
Device manufacturer Phillips-Medisize has announced that it will be acquired by Golden Gate Capital for an undisclosed amount. According to the announcement, Matt Jennings will remain as President and CEO, and the company will keep… Read more . . .
-
Discovery Laboratories has announced that the US Patent and Trademark Office (USPTO) has issued the company a new patent titled “Ventilation Circuit Adaptor and Proximal Aerosol Delivery System” (Patent No. 8,701,658) and Notices of Allowance… Read more . . .
-
According to 3M Drug Delivery Systems, the company will increase the capacity of its Loughborough, UK MDI facility by more than 20%. No additional details were provided. 3M DDS VP of Inhalation Drug Delivery Marcello… Read more . . .
-
Merck has announced the sale of its Consumer Care division, which markets Afrin oxymetazoline nasal spray, to Bayer. According to Bayer, “The purchase price of USD 14.2 billion includes a payment associated with sales of… Read more . . .
-
Decision Resources Group says that a survey of US payers found that 90 percent said they would pay a premium for a new treatment that does a significantly better job of reducing asthma exacerbations than… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA